Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Q3 2025 earnings

Reported November 12, 2025 · Before market open

Revenue-
EPS-$0.88Beat by $0.04
EPS estimate-$0.92

Next report

Date not yet announced

Financials

Q3 2025

Income statement

See full
Revenue-—
Operating income-$22.9M-24.9%
Net income-$21.5M-23.2%
EPS (diluted)-$0.88+4.3%

Balance sheet

See full
Cash & equivalents$26.0M-53.7%
Total debt$11.7M-21.9%
Total equity$129.2M-35.7%
Total assets$148.9M-34.0%

Cash flow

See full
Operating cash flow-$19.2M-65.4%
CapEx$600.0K+525%
Free cash flow-$19.8M-69.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$70.1M—
Enterprise value$55.82M—

Returns & leverage

See full
Return on equity-48%—
Debt / equity0.1×0.0×
Current ratio11.6×+0.3×

FAQ

When did Artiva Biotherapeutics, Inc. report Q3 2025 earnings?
Artiva Biotherapeutics, Inc. (ARTV) reported Q3 2025 earnings on November 12, 2025 before market open.
What were Artiva Biotherapeutics, Inc.'s Q3 2025 revenue and EPS?
Artiva Biotherapeutics, Inc. reported revenue of - and eps of $-0.88 for Q3 2025.
Did Artiva Biotherapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.92 by $0.04.
How did Artiva Biotherapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 4.3% from $-0.92.
Where can I find Artiva Biotherapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-275902) and the 10-Q periodic report (0001193125-25-275872) directly on SEC EDGAR. The filing index links above go to sec.gov.